Healthcare / Drug Manufacturers - GeneralShenzhen
$7.02
-0.20 (-2.77%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-145.6M · quality 64.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
32/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.3B
P/E
100.3x
↑EV/EBITDA
14.7x
↑ROE
1.1%
↑Gross Margin
24.9%
↓Debt/Equity
0.14
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-18.1%
FCF CAGR
—
FCF margin
-6.4%
FCF / Net income
-6.42x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.28B · net income $22.7M · FCF $-145.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.28B | $2.28B | $3.74B | $4.11B | $4.15B |
| Net Income | $22.7M | $22.7M | $34.7M | $81.6M | $77.9M |
| EBITDA | $144.2M | $144.2M | $157.9M | $214.0M | $198.9M |
| EPS | 0.07 | 0.07 | 0.10 | 0.24 | 0.23 |
| Gross Margin | 24.9% | 24.9% | 18.8% | 18.7% | 18.2% |
| Operating Margin | 0.6% | 0.6% | 1.4% | 2.4% | 2.7% |
| Net Margin | 1.0% | 1.0% | 0.9% | 2.0% | 1.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.14 | 0.14 | 0.25 | 0.04 | 0.04 |
| Current Ratio | 1.83 | 1.83 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-145.6M | $-145.6M | $-255.3M | $-103.2M | $-124.1M |
| Returns | |||||
| ROE | 1.1% | 1.1% | 1.8% | 4.1% | 4.1% |
| Valuation | |||||
| P/E | 100.29 | 100.29 | 73.70 | 44.46 | 34.48 |
| EV/EBITDA | 14.72 | 14.72 | 15.77 | 15.22 | 11.64 |
| P/B | 1.15 | 1.15 | 1.31 | 1.84 | 1.40 |
| Growth & Yield | |||||
| Revenue Growth | -39.2% | -39.2% | -8.9% | -0.9% | — |
| EPS Growth | -30.0% | -30.0% | -58.3% | 4.3% | — |
| Dividend Yield | 0.8% | 0.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
107.2%
EPS terminal req.
$0.62
Spread vs growth
-137.2%
5Y implied EPS CAGR
60.9%
EPS terminal req.
$0.75
Spread vs growth
-90.9%
10Y implied EPS CAGR
33.0%
EPS terminal req.
$1.21
Spread vs growth
-63.0%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-14.1%
Start / end P/E
82.5x → 100.3x
EPS bridge
0.10 → 0.07
Residual
-6.5%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.